What Is Jeuveau ("Newtox")? Cost, Duration & vs Botox (2026)

Jeuveau arrived in 2019 as the first botulinum toxin developed and marketed in the United States purely for cosmetic use, and the nickname that followed it, Newtox, tells you most of what people want to know: is this the same thing as Botox, is it as good, and is it cheaper? Those are fair questions, and they have real answers grounded in head to head clinical trials rather than clinic marketing. This guide explains what Jeuveau actually is, how it works inside a muscle, what it is approved to treat and what it is used for off-label, what a treatment appointment involves, how long results genuinely last, what can go wrong, what it costs, and how it compares with Botox, Dysport, Xeomin, and Daxxify. It also addresses the persistent rumor that Jeuveau was banned, which is a trade dispute story rather than a safety one.

FDA status: Jeuveau (prabotulinumtoxinA-xvfs) is FDA-approved only for the temporary improvement of moderate to severe glabellar (frown) lines in adults. Use anywhere else on the face, including forehead lines, crow's feet, a lip flip, or the masseter, is off-label. Jeuveau carries a boxed warning for distant spread of toxin effect. This guide is educational and is not a substitute for personalized medical advice.

What Jeuveau is

Jeuveau is the brand name for prabotulinumtoxinA-xvfs, a prescription botulinum toxin type A injectable distributed in the United States by Evolus, Inc. and manufactured by Daewoong Pharmaceutical in South Korea, where the same toxin is sold as Nabota. The U.S. Food and Drug Administration approved it in February 2019, and it reached American clinics that spring, making it the fourth botulinum toxin type A product to enter the U.S. aesthetic market after Botox, Dysport, and Xeomin, and the newest until Daxxify arrived in 2022.

The nickname Newtox came from the aesthetics industry rather than the manufacturer, and it stuck because Jeuveau's positioning was deliberately narrow. Where Botox built its business on medical indications first and cosmetic ones later, Jeuveau was brought to market solely as a cosmetic product. It has never been approved for chronic migraine, excessive sweating, cervical dystonia, or any other therapeutic condition. Evolus sells it exclusively into the cash-pay aesthetics market, which shapes both how it is priced and how it is promoted.

In the vial, Jeuveau is a sterile powder containing 100 units of botulinum toxin type A complex, stabilized with human serum albumin and sodium chloride, which a provider reconstitutes with preservative-free saline before injecting. Dosing is measured in units, not milliliters, and those units are specific to this product. Jeuveau is not a dermal filler and adds no volume anywhere. It works only by quieting muscle movement, which is why it treats expression lines rather than lost cheek or lip volume.

How Jeuveau works in the muscle

Every frown, squint, or raised eyebrow starts as a nerve signal. Nerve endings release a chemical messenger called acetylcholine at the junction where nerve meets muscle, and that messenger tells the muscle fiber to contract. Botulinum toxin type A, the active molecule in Jeuveau, binds to those nerve endings and blocks the release of acetylcholine. With the signal interrupted, the treated muscle relaxes and stops folding the skin above it. Over the glabella, the small patch of skin between the brows, that means the corrugator supercilii and procerus muscles stop drawing the brows together and the vertical elevens gradually soften.

The effect is deliberately local. Only the muscles that receive an injection are affected, and the toxin does not alter sensation, so the treated area still feels normal. The block is also temporary by design: over the following weeks and months, nerve endings sprout new connections, acetylcholine release resumes, and full muscle movement returns. This is the identical mechanism used by Botox, Dysport, Xeomin, and Daxxify. Nothing about Jeuveau's mode of action is novel, which is exactly why its clinical behavior tracks so closely with the older products.

Because the mechanism targets movement, Jeuveau performs best on dynamic wrinkles, the creases that appear when you make an expression and fade when your face is at rest. It performs less well on static lines already etched into the skin, the ones visible in a completely relaxed face. Those often need a dermal filler, a resurfacing treatment, or a combination approach, and a patient with deep resting glabellar creases should expect softening rather than erasure from any neuromodulator, Jeuveau included.

What Jeuveau treats: approved and off-label uses

Jeuveau has exactly one FDA-approved indication: the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator or procerus muscle activity in adults. That is the frown area between the eyebrows, and nothing else. The label states plainly that Jeuveau is not approved for the treatment of spasticity or any condition other than glabellar lines. This is narrower than Botox, which is approved for frown lines, crow's feet, and forehead lines cosmetically, plus a long list of medical uses.

In practice, injectors also use Jeuveau off-label across the rest of the upper face, most often for forehead lines and crow's feet, and occasionally for a lip flip, a bunny-line treatment, or masseter slimming. Off-label does not mean illegal, improper, or unsafe. It means the manufacturer has not sought or obtained FDA clearance for that use, so that area was not evaluated in the registration trials that support the label. Off-label use of botulinum toxin is routine, long-standing, and widely accepted across aesthetic medicine.

The honest caveat is about evidence rather than legality. Because Jeuveau was studied and approved only for the glabella, the published data on its dosing, duration, and diffusion in other facial zones is thinner than the data behind Botox in those same zones. A smaller split-face study comparing prabotulinumtoxinA-xvfs with onabotulinumtoxinA in the forehead and glabella found no statistically significant difference in onset, wrinkle appearance, or patient satisfaction, which is reassuring but is a single trial. Ask your injector which category your treatment falls into and what evidence supports it.

The Newtox nickname and the import ban that was not a safety recall

One of the most common searches about Jeuveau asks why it was banned, and the answer matters because the premise is misleading. Jeuveau was never withdrawn, recalled, or restricted by the FDA for safety reasons. Its approval has been continuous since February 2019. What happened was a commercial trade secret fight. Allergan and the South Korean manufacturer Medytox alleged that Daewoong, which makes Jeuveau, had misappropriated a botulinum strain and manufacturing know-how, and they brought the dispute before the U.S. International Trade Commission rather than a drug regulator.

In December 2020 the ITC issued a final determination imposing a 21-month import ban on the product. That order restricted bringing Jeuveau into the country. It was not a finding about purity, potency, or patient harm, and the FDA played no part in it. In February 2021, AbbVie, which by then owned Allergan, along with Medytox and Evolus, announced settlement agreements resolving the litigation. Evolus agreed to pay 35 million dollars plus royalties, and the parties petitioned the ITC to rescind the remedial orders with respect to Evolus, which cleared the way for continued U.S. commercialization.

The practical takeaway for a patient is straightforward. The Jeuveau in a licensed U.S. clinic today is an FDA-approved prescription drug supplied through the legitimate distribution chain, and the ban headlines refer to a resolved corporate dispute over manufacturing rights. What should concern you far more is product sourcing at the clinic level. Counterfeit and unapproved imported toxins do circulate, and the FDA has warned about them repeatedly. Ask to see the sealed vial and confirm you are receiving genuine Jeuveau from a licensed provider.

The procedure: what to expect at your appointment

A Jeuveau appointment is short, typically fifteen to thirty minutes including the consultation. Your provider should review your medical history, current medications, prior toxin treatments, and goals, then watch how your frown and brow muscles actually move, since dosing is driven by muscle strength and anatomy rather than by age or by a fixed formula. This screening step is not a formality. Botulinum toxin is inappropriate for some patients, and a good injector confirms candidacy before opening a vial.

The FDA-approved regimen for glabellar lines is 20 units total, given as five injections of 4 units each: two into each corrugator supercilii muscle and one into the procerus. Injections use a very fine needle and most people describe each one as a brief pinch or sting. Numbing cream or ice can help if you are sensitive, though many patients decline it. There is no anesthesia, no incision, and no meaningful downtime. You can drive yourself home and return to normal activity the same day.

Aftercare is simple and mostly about keeping the product where it was placed. Providers commonly advise staying upright for a few hours, skipping vigorous exercise, alcohol, and facials for the rest of the day, and not rubbing or massaging the treated area. Pinpoint bruising, mild redness, or small raised bumps at the injection sites are common and settle within hours to a few days. Nothing changes immediately in the mirror, because the muscle-relaxing effect builds over the following days. Many injectors offer a two-week review to assess the settled result before adjusting anything.

Results, onset, and how long Jeuveau lasts

Jeuveau starts working within a few days rather than immediately. Evolus reports visible improvement in as little as two days, and the full effect generally settles by around two weeks. Duration for most people is three to four months, the same window quoted for Botox, Dysport, and Xeomin, after which movement returns gradually and the lines reappear as they were before. Retreatment should not be given more often than every three months according to the label.

The efficacy data behind those numbers is solid for the frown area. In two identical phase 3 trials, EV-001 and EV-002, involving 654 adults with moderate to severe glabellar lines, a single 20-unit dose produced day-30 responder rates of 67.5 percent and 70.4 percent, where a responder required both the investigator and the patient to independently agree on a two-grade or greater improvement at maximum frown. Placebo responder rates were 1.2 and 1.3 percent. A separate European phase 3 study of 540 patients found 20 units of prabotulinumtoxinA non-inferior to 20 units of onabotulinumtoxinA, with responder rates of 87.2 and 82.8 percent respectively. Those two sets of percentages are not directly comparable, and the difference is worth understanding before you read too much into either. The U.S. trials used a deliberately strict bar that required the investigator and the patient to independently agree on a two-grade improvement, while the European study counted anyone the investigator rated as having no more than mild lines at maximum frown, which is why its numbers run so much higher. Both endpoints are legitimate; they simply measure different things.

A frequent question is whether Jeuveau wears off faster than Botox. The trial evidence does not support that. Duration is comparable, and where individuals report a shorter run it usually traces to dose, the strength of the muscle treated, the area injected, individual metabolism, or injector technique rather than to the brand on the vial. Nothing about any neurotoxin is guaranteed, results vary between people and between treatments in the same person, and off-label areas such as the forehead have less published duration data than the glabella does.

Safety, side effects, and risks

Jeuveau carries the class boxed warning that appears on every botulinum toxin product, the FDA's most serious warning format. It states that the effects of the toxin may spread from the injection area to produce symptoms consistent with botulinum toxin effects, that these have been reported hours to weeks after injection, and that swallowing and breathing difficulties can be life threatening, with reports of death. These events are associated overwhelmingly with high therapeutic doses rather than the small cosmetic doses used for frown lines, but anyone who develops trouble swallowing, speaking, breathing, or new muscle weakness after treatment should seek medical care immediately.

Far more common are mild and temporary effects. In the pivotal trials the most frequently reported adverse reactions were headache, seen in about 12 percent of patients, upper respiratory tract infection in about 3 percent, eyelid ptosis in about 2 percent, and increased white blood cell count in about 1 percent. Bruising, redness, swelling, and tenderness at the injection sites are also routine. No serious adverse event in either phase 3 study was judged related to the study drug.

The cosmetic complications patients worry about most, a drooping brow or eyelid or an asymmetric, overly frozen look, generally result from product affecting a neighboring muscle rather than from the drug being unsafe. They are temporary and resolve as the effect wears off, but they can take weeks to do so. Jeuveau is contraindicated with a known hypersensitivity to botulinum toxin preparations and with infection at the planned injection site, and it is not recommended in pregnancy or breastfeeding. Tell your provider about neuromuscular disorders such as myasthenia gravis, Lambert-Eaton syndrome, or ALS, and about aminoglycoside antibiotics, muscle relaxants, and blood thinners. Injector skill and anatomical knowledge remain the single largest factor in avoiding problems.

Jeuveau compared with Botox, Dysport, Xeomin, and Daxxify

All five major neuromodulators are botulinum toxin type A and work through the same acetylcholine block, so the meaningful differences lie in formulation, breadth of approval, onset, duration, and price rather than in what they fundamentally do. Jeuveau's distinguishing traits are its cosmetic-only positioning, its Korean manufacturing origin, and a price point that clinics often set slightly below Botox. The table below sets out the practical comparison points.

On the frown area specifically, the evidence says Jeuveau and Botox perform comparably: the European head to head trial established non-inferiority at matched 20-unit doses, and a smaller split-face study found no statistically significant difference in onset, wrinkle appearance, or patient satisfaction in the forehead and glabella. Jeuveau's advantage is usually price and a marketing claim of faster onset that the head to head data does not clearly confirm. Botox's advantages are a two-decade real-world safety record, a wider set of on-label cosmetic areas, and medical indications that matter if you also treat migraine or excessive sweating.

Two cautions apply across the whole class. First, units are not interchangeable between brands. Jeuveau and Botox happen to share a roughly one-to-one glabellar dose, but Dysport units are entirely different and Daxxify units are its own scale, so comparing brands on price per unit is only meaningful where the dosing scales genuinely match. Second, for most patients the variable that determines how natural, symmetric, and durable the result looks is the person holding the syringe, not the label on the vial. Choosing a skilled injector matters more than choosing between these products.

Cost: what Jeuveau typically runs

Jeuveau is a cash-pay cosmetic treatment and is not covered by insurance. Clinics price it either per unit or as a flat fee for a treatment area, and the figure varies substantially with geography, the injector's credentials and experience, the practice setting, and the number of units your anatomy requires. As a general pattern, clinics position Jeuveau at or slightly below their Botox price, which is part of how Evolus has grown the brand. Because pricing is set locally and changes over time, treat any number you find online as an estimate and confirm the real figure with the clinic at consultation.

The unit count is what actually drives the bill. The approved glabellar treatment is 20 units, so a frown-line-only appointment sits at the lower end of the range. Adding off-label areas raises it: the forehead commonly takes another 10 to 20 units and crow's feet another 20 to 24 across both sides, so a full upper-face treatment can easily run two to three times the cost of the glabella alone. Ask for a written quote that specifies both the price per unit and the planned unit count, because a low per-unit price paired with a high unit count is not a bargain.

Two things are worth watching. Deeply discounted toxin can signal over-dilution, an inexperienced injector, or product sourced outside the legitimate supply chain, all of which carry real risk. And because results last three to four months, the honest way to budget is annually rather than per visit, at roughly three treatments a year to maintain a consistent look. Manufacturer loyalty programs, including the Evolus Rewards program, can offset part of the cost, though they should never be the deciding factor in choosing a provider or a product.

Candidacy and choosing an injector

Jeuveau suits healthy adults who are bothered by moderate to severe frown lines that appear or deepen with expression, and who want a temporary, non-surgical way to soften them. It is a reasonable first neurotoxin because the dose and duration are conventional, so nothing about the experience commits you to a long hold if you dislike the result. It is a poor fit if your primary concern is volume loss, skin texture, or lines fully etched at rest, which call for fillers, biostimulators, or resurfacing instead. It is not appropriate in pregnancy or breastfeeding, with an active infection at the injection site, with a known hypersensitivity to botulinum toxin, or with certain neuromuscular conditions. Only an in-person medical evaluation can confirm you are a candidate.

The provider decision matters more than the product decision. Look for a licensed medical professional who injects neurotoxins regularly: a board-certified dermatologist or plastic surgeon, or a qualified nurse injector or physician assistant working under appropriate medical supervision. They should examine your muscle movement rather than quoting a standard dose, explain which areas are on-label and which are off-label, discuss the boxed warning and realistic risks, and show you the sealed, genuine vial.

A good consultation feels like a clinical conversation rather than a sales pitch. Useful questions to ask: how many units do you recommend for my anatomy and why, is the area you are proposing on-label for Jeuveau, what should I expect at two weeks, what happens if the result is uneven or falls short, and would Botox, Dysport, Xeomin, or Daxxify serve me better than Jeuveau. A trustworthy injector will tell you plainly when a different product or a different treatment altogether is the better answer for your face. When you are ready, compare qualified injectors near you and book a consultation.